Toll-like receptors as therapeutic targets for cancer.


Stimulation of Toll-like receptors (TLRs) to activate the innate immune system has been a legitimate therapeutic strategy for some years. TLRs 3, 4, 7, 8 and 9 are all validated targets for cancer and a number of companies are developing agonists and vaccine adjuvants. TLR7 in particular has established proof-of-concept as a target in the topical treatment… (More)
DOI: 10.1016/j.drudis.2013.08.020


Cite this paper

@article{Holldack2014TolllikeRA, title={Toll-like receptors as therapeutic targets for cancer.}, author={Johanna Holldack}, journal={Drug discovery today}, year={2014}, volume={19 4}, pages={379-82} }